[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2020007627A - Uso de la carrimicina o de sus ingredientes activos. - Google Patents

Uso de la carrimicina o de sus ingredientes activos.

Info

Publication number
MX2020007627A
MX2020007627A MX2020007627A MX2020007627A MX2020007627A MX 2020007627 A MX2020007627 A MX 2020007627A MX 2020007627 A MX2020007627 A MX 2020007627A MX 2020007627 A MX2020007627 A MX 2020007627A MX 2020007627 A MX2020007627 A MX 2020007627A
Authority
MX
Mexico
Prior art keywords
isovalerylspiramycin
active ingredient
carrimycin
iii
drug
Prior art date
Application number
MX2020007627A
Other languages
English (en)
Inventor
Xiaofeng Zhao
Mingyu Xia
Xunlei Jiang
Xundong Jiang
Original Assignee
Shenyang Fuyang Pharmaceutical Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenyang Fuyang Pharmaceutical Tech Co Ltd filed Critical Shenyang Fuyang Pharmaceutical Tech Co Ltd
Publication of MX2020007627A publication Critical patent/MX2020007627A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describe un medicamento para prevenir y/o tratar una enfermedad, la enfermedad es enfermedad de Alzheimer, diabetes o senilidad; y el medicamento incluye un primer ingrediente activo, y el primer ingrediente activo incluye uno de carrimicina, isovalerilespiramicina I, isovalerilespiramicina II e isovalerilespiramicina III, o una combinación de dos o tres de isovalerilespiramicina I, isovalerilespiramicina II e isovalerilespiramicina III.
MX2020007627A 2018-01-19 2019-01-18 Uso de la carrimicina o de sus ingredientes activos. MX2020007627A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201810052732 2018-01-19
CN201810053060 2018-01-19
CN201810052558 2018-01-19
PCT/CN2019/072413 WO2019141256A1 (zh) 2018-01-19 2019-01-18 可利霉素或其活性成分的用途

Publications (1)

Publication Number Publication Date
MX2020007627A true MX2020007627A (es) 2020-11-24

Family

ID=67301318

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007627A MX2020007627A (es) 2018-01-19 2019-01-18 Uso de la carrimicina o de sus ingredientes activos.

Country Status (9)

Country Link
US (1) US11413302B2 (es)
EP (1) EP3741373B1 (es)
JP (1) JP7152052B2 (es)
KR (1) KR20200112898A (es)
AU (1) AU2019209740A1 (es)
CA (1) CA3088823A1 (es)
MX (1) MX2020007627A (es)
RU (1) RU2771046C2 (es)
WO (1) WO2019141256A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019141254A1 (zh) * 2018-01-19 2019-07-25 沈阳福洋医药科技有限公司 一种mTOR抑制剂、药物组合物及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2765876B2 (ja) * 1988-10-24 1998-06-18 科研製薬株式会社 ピリジルケトオキシムエーテル誘導体
CN1237976C (zh) 2003-12-23 2006-01-25 沈阳同联集团有限公司 必特螺旋霉素及其在抗感染性疾病中的应用
CA2556622A1 (en) 2004-03-02 2005-09-15 Wyeth Macrolides and methods for producing same
WO2007144876A1 (en) 2006-06-12 2007-12-21 Ramot At Tel-Aviv University Ltd. Methods for treating cancer
WO2011056961A2 (en) * 2009-11-04 2011-05-12 Health Research Inc. Method and compositions for suppression of aging
CN101785779B (zh) * 2010-03-09 2014-03-05 沈阳同联集团有限公司 异戊酰螺旋霉素ii的分离制备
WO2011110084A1 (zh) 2010-03-09 2011-09-15 沈阳同联集团有限公司 异戊酰螺旋霉素ⅰ、ⅱ或ⅲ的分离制备方法、及含有它们的药用组合物及其应用
CN101785778A (zh) * 2010-03-09 2010-07-28 沈阳同联集团有限公司 异戊酰螺旋霉素i的分离制备及其应用
CN101773510B (zh) 2010-03-09 2013-06-05 沈阳同联集团有限公司 异戊酰螺旋霉素iii的分离制备
DK3210990T3 (da) * 2010-05-25 2020-03-23 Shenyang Fuyang Pharmaceutical Tech Co Ltd Levoisovalerylspiramycin iii og præparater, fremstillingsfremgangsmåder og anvendelser deraf
RU2593499C2 (ru) 2010-05-25 2016-08-10 Шенянг Тонглиан Груп Ко., Лтд. Лекарственная форма левокарримицина, способ его получения и использования
KR101271593B1 (ko) 2010-07-16 2013-06-11 대우제약 주식회사 마크로락틴 에이 및 그 유도체를 유효성분으로 함유하는 항혈관신생효과를 갖는 조성물
ES2623176T3 (es) * 2012-08-16 2017-07-10 Teva Pharmaceutical Industries Ltd. Composición farmacéutica de memantina
US9738676B2 (en) 2012-12-31 2017-08-22 Basilea Pharmaceutica Ag Selected macrolides with PDE4-inhibiting activity
JP6959355B2 (ja) 2017-04-06 2021-11-02 沈陽福洋医薬科技有限公司Ｓｈｅｎｙａｎｇ Ｆｕｙａｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．， Ｌｔｄ 腫瘍を治療および／または予防する薬物の調製におけるカリマイシンおよびその薬学的に許容可能な塩の応用
EP3639829B1 (en) 2017-07-04 2022-02-09 Shenyang Fuyang Pharmaceutical Technology Co., Ltd. Use of isovalerylspiramycin i or iii in preparation of drug for treating and/or preventing tumour, and drug
WO2019141254A1 (zh) * 2018-01-19 2019-07-25 沈阳福洋医药科技有限公司 一种mTOR抑制剂、药物组合物及其应用

Also Published As

Publication number Publication date
EP3741373B1 (en) 2022-10-12
US11413302B2 (en) 2022-08-16
RU2020126396A3 (es) 2022-02-21
EP3741373A4 (en) 2021-03-10
US20200338107A1 (en) 2020-10-29
JP7152052B2 (ja) 2022-10-12
RU2771046C2 (ru) 2022-04-25
JP2021517887A (ja) 2021-07-29
EP3741373A1 (en) 2020-11-25
AU2019209740A1 (en) 2020-09-10
KR20200112898A (ko) 2020-10-05
RU2020126396A (ru) 2022-02-21
WO2019141256A1 (zh) 2019-07-25
CA3088823A1 (en) 2019-07-25

Similar Documents

Publication Publication Date Title
MX2020007625A (es) Inhibidor mtor, composicion farmaceutica y su uso.
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
SA518400356B1 (ar) مثبطات الأرجيناز واستخداماتها العلاجية
PH12020551578A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
PH12021550605A1 (en) Farnesoid x receptor agonists and uses thereof
BR112019001923A2 (pt) moduladores de nmda de espiro-lactama e métodos de sua utilização
MX2018014202A (es) Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos.
CR20220215A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
WO2018071741A8 (en) Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
EP4427815A3 (en) Deuterium-enriched pirfenidone and methods of use thereof
MX2022004678A (es) Anticuerpo anti-beta amiloide para el tratamiento de la enfermedad de alzheimer.
WO2019166412A9 (en) Modulation of pla2-g1b in therapy
WO2018115432A3 (en) COMPOUNDS FOR THE TREATMENT OF BOVINE OR PORCINE RESPIRATORY DISEASE
AU2018326364A1 (en) Methods of enhancing and/or stabilizing cardiac function in patients with Fabry disease
EP3922264A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION, IMPROVEMENT OR TREATMENT OF SKIN DISEASES
MX2021007235A (es) Tubulisinas y conjugados de proteina-tubulisina.
MX2023006419A (es) Compuestos polipéptidos modificados con lactama.
EP4043012A4 (en) MEDICINAL PRODUCTS FOR TREATING ARTERY DISEASES AND USE THEREOF
MX2020007627A (es) Uso de la carrimicina o de sus ingredientes activos.
GEP20207136B (en) Antiseptic composition comprising polyvinylpyrrolidone and unithiol and use of the composition
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
MX2022005388A (es) Compuestos de pirrolidina y piperidina.
WO2016191458A3 (en) Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment
EP3844168A4 (en) COMBINATION DRUG PREPARATIONS FOR THE TREATMENT OF PATIENTS WITH CARDIOVASCULAR DISEASE AND ASSOCIATED CONDITIONS